AI readiness for molecular precision medicine supply chains: evidence from Saudi Arabia.

INTRODUCTION: Artificial intelligence (AI) is reshaping molecular precision medicine through biomarker discovery, genomic variant interpretation, molecular imaging, multi-omics analysis, and patient-specific therapeutic support. In Saudi Arabia, genomic medicine and digital health initiatives are expanding, yet limited evidence explains how AI readiness supports molecular diagnostics, genomic testing, biobanking, biological sample traceability, and targeted therapy delivery. METHODS: A structured cross-sectional survey was completed by 350 professionals from hospitals, molecular diagnostic laboratories, genomic testing centers, biomedical laboratories, biobanks, pharmaceutical and biologic suppliers, and healthcare service providers in Saudi Arabia. Data were analyzed using partial least squares structural equation modeling. RESULTS: AI readiness strengthened molecular data interoperability, biological sample traceability, diagnostic responsiveness, biomarker-guided decision support, and precision medicine service performance. Respondents from more AI-ready organizations reported stronger diagnostic responsiveness and fewer perceived workflow delays. DISCUSSION: The findings connect AI readiness with molecular diagnostics, genomic services, biomarker analytics, biobanking, and healthcare supply chain coordination, providing evidence to support AI-enabled molecular medicine transformation in Saudi Arabia.